Skip to Main Content

Hello, everyone, and how are you this morning? We are doing just fine, thank you, as we prepare to wind down a busy trip to both the STAT nerve center and the Woodstock-like gathering of biotech types. Perhaps you were here, too. Sorry if we missed you, though. So many people and so little time. In any event, we are now busy foraging for two things — decent cups of stimulation and items of interest. While we hunt and gather, here are a few tidbits to help you along. Hope your day is manageable and, as always, do keep in touch. We appreciate secrets of all sorts …

Pfizer (PFE) issued a nationwide recall of two lots of naloxone, the opioid overdose antidote medicine, because of the potential presence of embedded and loose particulate matter on the syringe plunger, according to this notice. The product, which is widely used in the wake of the opioid crisis, is made by its Hospira unit that has caused the big drug maker considerable headaches. Since paying $15 billion for Hospira three years ago, Pfizer has encountered a string of production problems for numerous products, such as opioid-filled syringes, which have led to disruptive shortages.


A Philippine lawmaker is urging the Department of Health to seek a full refund from Sanofi (SNY) for its dengue vaccine that was used in an immunization campaign, The Philippine Star reports. Sanofi already agreed to refund about $29 million for unused Dengvaxia vaccine, but Rep. Karlo Nograles, who chairs the House appropriations committee, believes the government is entitled to a full refund so it could help thousands of schoolchildren who received the vaccine in 2016 and 2017. The government previously threatened to sue Sanofi for not issuing refunds for all vaccine that was used.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!